Pierre-Louis Soubeyran

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8734013/publications.pdf

Version: 2024-02-01

184 papers	12,919 citations	41323 49 h-index	24232 110 g-index
193 all docs	193 docs citations	193 times ranked	13305 citing authors

#	Article	IF	Citations
1	Information needs of older patients newly diagnosed with cancer. Journal of Geriatric Oncology, 2022, 13, 265-272.	0.5	3
2	What Defines Quality of Life for Older Patients Diagnosed with Cancer? A Qualitative Study. Cancers, 2022, 14, 1123.	1.7	12
3	Patient Preferences for Treatment Outcomes in Oncology with a Focus on the Older Patientâ€"A Systematic Review. Cancers, 2022, 14, 1147.	1.7	34
4	Exploring Determinants of Interdisciplinary Collaboration within a Geriatric Oncology Setting: A Mixed-Method Study. Cancers, 2022, 14, 1386.	1.7	2
5	Does Inflammation Contribute to Cancer Incidence and Mortality during Aging? A Conceptual Review. Cancers, 2022, 14, 1622.	1.7	6
6	Geriatric assessment in the management of older patients with cancer â€" A systematic review (update). Journal of Geriatric Oncology, 2022, 13, 761-777.	0.5	67
7	Health literacy in patients with cancer: A multicenter national study.. Journal of Clinical Oncology, 2022, 40, 6541-6541.	0.8	0
8	Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1â€driven acute lymphoblastic leukemia. Molecular Oncology, 2021, 15, 1412-1431.	2.1	16
9	Covid-19 Pandemic and Geriatric Oncology. , 2021, , 1-8.		0
10	Tumors: Lymphomas. , 2021, , 1-10.		0
11	Geriatric Assessment and Management in Cancer. Journal of Clinical Oncology, 2021, 39, 2058-2067.	0.8	57
12	Two parallel pathways connect glutamine metabolism and mTORC1 activity to regulate glutamoptosis. Nature Communications, 2021, 12, 4814.	5.8	19
13	Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. Breast, 2021, 60, 138-146.	0.9	5
14	Targeting CAMKK2 and SOC Channels as a Novel Therapeutic Approach for Sensitizing Acute Promyelocytic Leukemia Cells to All-Trans Retinoic Acid. Cells, 2021, 10, 3364.	1.8	7
15	Tumors: Lymphomas. , 2021, , 5251-5260.		0
16	COVID-19 Pandemic and Geriatric Oncology. , 2021, , 1198-1206.		0
17	Cognitive Impairment in Older Cancer Patients Treated with First-Line Chemotherapy. Cancers, 2021, 13, 6171.	1.7	6
18	Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts. Cancers, 2021, 13, 6154.	1.7	4

#	Article	IF	Citations
19	Management and outcome of primary CNS lymphoma in the modern era. Neurology, 2020, 94, e1027-e1039.	1.5	125
20	Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood, 2020, 135, 1811-1815.	0.6	17
21	Triarylpyridine Compounds and Chloroquine Act in Concert to Trigger Lysosomal Membrane Permeabilization and Cell Death in Cancer Cells. Cancers, 2020, 12, 1621.	1.7	8
22	Taking care of older patients with cancer in the context of COVID-19 pandemic. Lancet Oncology, The, 2020, 21, e236.	5.1	13
23	Perspectives on cancer care in older patients in France. Ecancermedicalscience, 2020, 14, 1103.	0.6	1
24	Abstract P1-19-19: Treatments and outcome in older versus younger women with HER2-positive metastatic breast cancer in the multicenter national observational ESME database. , 2020, , .		0
25	Development of a self-reported version of the G8 screening tool. Journal of Geriatric Oncology, 2019, 10, 926-930.	0.5	22
26	A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer. Journal of Geriatric Oncology, 2019, 10, 847-858.	0.5	119
27	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. Neuro-Oncology, 2019, 21, 1039-1048.	0.6	13
28	Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells. Cancers, 2019, 11, 291.	1.7	13
29	Determinants of functional decline in older adults experiencing cancer (the INCAPAC study). Journal of Geriatric Oncology, 2019, 10, 913-920.	0.5	16
30	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. Journal of Clinical Oncology, 2019, 37, 823-833.	0.8	184
31	Modulation of the ATM/autophagy pathway by a G-quadruplex ligand tips the balance between senescence and apoptosis in cancer cells. Nucleic Acids Research, 2019, 47, 2739-2756.	6.5	50
32	Approaches for vulnerable and frail older patients with diffuse large B-cell lymphomas. Current Opinion in Oncology, 2019, 31, 369-373.	1.1	6
33	The prognostic value of G8 for functional decline. Journal of Geriatric Oncology, 2019, 10, 921-925.	0.5	20
34	Using machine learning to predict mortality in older patients with cancer: Decision tree and random forest analyses from the ELCAPA and ONCODAGE prospective cohorts.. Journal of Clinical Oncology, 2019, 37, 11516-11516.	0.8	2
35	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Annals of Oncology, 2018, 29, 544-562.	0.6	64
36	Alterations in comprehensive geriatric assessment decrease survival of elderly patients with cancer. European Journal of Cancer, 2018, 90, 10-18.	1.3	30

#	Article	IF	Citations
37	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood, 2018, 131, 174-181.	0.6	121
38	Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: A systematic review of the literature focused on the elderly. Journal of Geriatric Oncology, 2018, 9, 6-14.	0.5	22
39	Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work. Breast Cancer Research and Treatment, 2018, 168, 433-441.	1.1	4
40	Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination. Cancers, 2018, 10, 402.	1.7	7
41	Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey. European Journal of Cancer, 2018, 103, 61-68.	1.3	48
42	mTOR Inhibition via Displacement of Phosphatidic Acid Induces Enhanced Cytotoxicity Specifically in Cancer Cells. Cancer Research, 2018, 78, 5384-5397.	0.4	14
43	Bendamustine and rituximab in elderly patients with lowâ€tumour burden follicular lymphoma. Results of the <scp>LYSA</scp> phase <scp>II BRIEF</scp> study. British Journal of Haematology, 2018, 183, 76-86.	1.2	14
44	Determinants of cancer treatment and mortality in older cancer patients using a multi-state model: Results from a population-based study (the INCAPAC study). Cancer Epidemiology, 2018, 55, 39-44.	0.8	8
45	Predictive factors of depressive symptoms of elderly patients with cancer receiving first-line chemotherapy. Psycho-Oncology, 2017, 26, 15-21.	1.0	29
46	Major depressive disorder and associated factors in elderly patients with non-Hodgkinâ€™s lymphoma. Health Psychology and Behavioral Medicine, 2017, 5, 57-65.	0.8	4
47	mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation. Nature Communications, 2017, 8, 14124.	5.8	62
48	Unmet needs in the scientific approach to older patients with lymphoma. Haematologica, 2017, 102, 972-975.	1.7	17
49	Modeling individual and relative accuracy of screening tools in geriatric oncology. Annals of Oncology, 2017, 28, 1152-1157.	0.6	10
50	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematology,the, 2017, 4, e35-e45.	2.2	33
51	Rational therapeutic choice for older patients with lymphoma. Current Opinion in Oncology, 2017, 29, 322-327.	1.1	10
52	Immune checkpoint inhibitors and elderly people: AÂreview. European Journal of Cancer, 2017, 82, 155-166.	1.3	148
53	Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients. OncoTargets and Therapy, 2016, Volume 9, 6689-6693.	1.0	4
54	Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. Journal of Clinical Oncology, 2016, 34, 2575-2582.	0.8	142

#	Article	IF	Citations
55	Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology, 2016, 19, now238.	0.6	30
56	Treatment of the elderly patient with mantle cell lymphoma. Hematology American Society of Hematology Education Program, 2016, 2016, 425-431.	0.9	6
57	Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly. Hematology American Society of Hematology Education Program, 2016, 2016, 432-436.	0.9	3
58	Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version. Oncologist, 2016, 21, 188-195.	1.9	85
59	Innovative approach to older patients with malignant hemopathies. Haematologica, 2016, 101, 893-895.	1.7	6
60	Hodgkin lymphoma: a negative interimâ€‹scp›PET‹/scp› cannot circumvent the need for endâ€‹ofâ€‹treatmentâ€‹scp›PET‹/scp› evaluation. British Journal of Haematology, 2016, 175, 652-660.	1.2	23
61	Targeted therapy and elderly people: A review. European Journal of Cancer, 2016, 69, 199-215.	1.3	34
62	Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial. BMC Cancer, 2016, 16, 932.	1.1	33
63	Detection of frailty in elderly cancer patients: Improvement of the G8 screening test. Journal of Geriatric Oncology, 2016, 7, 99-107.	0.5	55
64	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro-Oncology, 2016, 18, 1297-1303.	0.6	135
65	Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS). Blood, 2016, 128, 782-782.	0.6	21
66	The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?. Blood, 2016, 128, 926-926.	0.6	2
67	One-Year Mortality in Older Patients with Cancer: Development and External Validation of an MNA-Based Prognostic Score. PLoS ONE, 2016, 11, e0148523.	1.1	50
68	Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematology,the, 2015, 2, e251-e259.	2.2	164
69	Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper. Journal of Geriatric Oncology, 2015, 6, 141-152.	0.5	61
70	Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas. Journal of Immunology, 2015, 195, 2207-2215.	0.4	26
71	Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Annals of Oncology, 2015, 26, 1058-1068.	0.6	67
72	Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. Journal of Clinical Oncology, 2015, 33, 1482-1490.	0.8	60

#	Article	IF	Citations
73	Impact of comorbidities on the treatment of non-Hodgkinâ€™s lymphoma: a systematic review. Expert Review of Hematology, 2015, 8, 329-341.	1.0	18
74	Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 2035-2035.	0.8	5
75	General Considerations on Treatment in Older Patients with Hematological Malignancies. , 2015, , 253-268.		0
76	Validation of a geriatric screening test to detect frailty in elderly cancer patients: Improving the G8 test.. Journal of Clinical Oncology, 2015, 33, e12604-e12604.	0.8	0
77	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia, 2014, 28, 2367-2375.	3.3	281
78	p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells. Cell Death and Differentiation, 2014, 21, 1852-1861.	5.0	53
79	BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study. BMC Cancer, 2014, 14, 503.	1.1	21
80	R-CHOP with or without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL): Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group. Blood, 2014, 124, 393-393.	0.6	15
81	Nutritional Advice in Older Patients at Risk of Malnutrition during Treatment for Chemotherapy: A Two-Year Randomized Controlled Trial. PLoS ONE, 2014, 9, e108687.	1.1	96
82	Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study. PLoS ONE, 2014, 9, e115060.	1.1	437
83	New Drugs for Follicular Lymphoma in Older Adults. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 657-664.	0.9	2
84	Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study. Blood, 2014, 124, 4430-4430.	0.6	0
85	Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey. Anticancer Research, 2014, 34, 5007-15.	0.5	3
86	Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature. Psycho-Oncology, 2013, 22, 241-249.	1.0	72
87	Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkinâ€™s lymphoma: A systematic review. Cancer Treatment Reviews, 2013, 39, 812-817.	3.4	35
88	Modeling of treatment response to erythropoiesis-stimulating agents in older (ageâ‰¥70years) and younger (age<70years) patients with cancer and anemia: Findings from the Anemia Cancer Treatment study. Journal of Geriatric Oncology, 2013, 4, 196-201.	0.5	0
89	Screening methods for geriatric frailty. Lancet Oncology, The, 2013, 14, e1-e2.	5.1	20
90	From suboptimal to optimal treatment in older patients with cancer. Journal of Geriatric Oncology, 2013, 4, 291-293.	0.5	11

#	Article	IF	Citations
91	Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy. Journal of Clinical Oncology, 2013, 31, 3877-3882.	0.8	201
92	⁹⁰Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial. Journal of Clinical Oncology, 2013, 31, 1977-1983.	0.8	192
93	IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia, 2013, 27, 183-189.	3.3	169
94	Management of elderly patients with chronic lymphocytic leukemia. Hematologie, 2013, 19, 10-20.	0.0	0
95	Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. Blood, 2013, 122, 509-509.	0.6	66
96	Reply to J. Lagro et al. Journal of Clinical Oncology, 2012, 30, 4443-4445.	0.8	2
97	Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Annals of Oncology, 2012, 23, 2166-2172.	0.6	724
98	Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas. Clinical Cancer Research, 2012, 18, 5203-5211.	3.2	210
99	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood, 2012, 120, 2650-2657.	0.6	56
100	Impact of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With Highâ€"Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. Journal of Clinical Oncology, 2012, 30, 4317-4322.	0.8	168
101	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Annals of Oncology, 2012, 23, 2380-2385.	0.6	48
102	Therapeutic strategies in elderly and very elderly patients. Best Practice and Research in Clinical Haematology, 2012, 25, 91-100.	0.7	6
103	Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naÃ¯ve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. Journal of Hematology and Oncology, 2012, 5, 67.	6.9	16
104	The EORTC Cancer in the Elderly Task Force, a Protostar for EORTC's future. European Journal of Cancer, Supplement, 2012, 10, 34-38.	2.2	8
105	Referral of elderly cancer patients to specialists: Action proposals for general practitioners. Cancer Treatment Reviews, 2012, 38, 935-941.	3.4	15
106	General joint frailty model for recurrent event data with a dependent terminal event: Application to follicular lymphoma data. Statistics in Medicine, 2012, 31, 1162-1176.	0.8	35
107	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. Blood, 2012, 120, 906-906.	0.6	5
108	Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer. Journal of Clinical Oncology, 2012, 30, 1829-1834.	0.8	366

#	Article	IF	Citations
109	Prognostic factors of the loss of autonomy (LoA) in older patients with cancer receiving first-line chemotherapy.. Journal of Clinical Oncology, 2012, 30, 9012-9012.	0.8	0
110	Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies.. Blood, 2012, 120, 2712-2712.	0.6	0
111	Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: A first-line phase II study. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 823-830.	0.7	12
112	Chemotherapy treatment for older women with metastatic breast cancer: What is the evidence?. Cancer Treatment Reviews, 2011, 37, 590-598.	3.4	8
113	Consolidation par 90Y-epratuzumab en fractionnÃ© dans le lymphome B diffus Ã grandes cellulesÂ: rÃ©sultats prÃ©liminaires dâ€™une Ã©tude de phase II. Medecine Nucleaire, 2011, 35, 478-486.	0.2	0
114	Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly. Journal of Geriatric Oncology, 2011, 2, 36-44.	0.5	36
115	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, The, 2011, 377, 42-51.	6.3	957
116	Huit fiches pratiques de conseil nutritionnel pour rÃ©pondre aux besoins des patients Ã¢gÃ©s au cours de leur traitement de chimiothÃ©rapie: Ã©tude INOGAD. Oncologie, 2011, 13, 83-89.	0.2	5
117	Ã‰valuation gÃ©riatrique dans les hÃ©mopathies lymphoÃ¯des. Oncologie, 2011, 13, 589-594.	0.2	0
118	Factors influencing general practitioners in the referral of elderly cancer patients. BMC Cancer, 2011, 11, 5.	1.1	32
119	Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Annals of Oncology, 2011, 22, 257-267.	0.6	148
120	Promoting evidence-based management of anemia in cancer patients: concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer. Supportive Care in Cancer, 2010, 18, 847-858.	1.0	11
121	R126 QualitÃ© de vie des patients atteints dâ€™un cancer hÃ©matologique et facteurs psychosociaux associÃ©s : une revue de la littÃ©rature internationale. Bulletin Du Cancer, 2010, 97, S65.	0.6	0
122	Overview of aggressive lymphomas in the older adult. Aging Health, 2010, 6, 191-200.	0.3	0
123	Occupational exposure to organic solvents and lymphoid neoplasms in men: results of a French case-control study. Occupational and Environmental Medicine, 2010, 67, 664-672.	1.3	16
124	Questionnaires and instruments for a multidimensional assessment of the older cancer patient: What clinicians need to know?. European Journal of Cancer, 2010, 46, 1019-1025.	1.3	72
125	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients. Blood, 2010, 116, 2875-2875.	0.6	10
126	90Y-Ibritumomab Tiuxetan (ZevalinÂ®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients. Blood, 2010, 116, 594-594.	0.6	9

#	Article	IF	Citations
127	Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study. Annals of Oncology, 2009, 20, 1714-1721.	0.6	8
128	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. Journal of Clinical Oncology, 2009, 27, 4555-4562.	0.8	613
129	Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: A French caseâ€"control study. International Journal of Cancer, 2009, 124, 1188-1195.	2.3	8
130	Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study. Occupational and Environmental Medicine, 2009, 66, 291-298.	1.3	93
131	Management of unfit patients with unfavourable non-Hodgkinâ€™s lymphomas. Cancer Treatment Reviews, 2009, 35, 528-532.	3.4	6
132	Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study. European Journal of Cancer, 2009, 45, 8-11.	1.3	20
133	Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study. European Journal of Cancer, 2009, 45, 1603-1615.	1.3	54
134	UV radiation exposure, skin type and lymphoid malignancies: results of a French caseâ€"control study. Cancer Causes and Control, 2008, 19, 305-315.	0.8	28
135	Cigarette smoking, alcohol drinking, and risk of lymphoid neoplasms: results of a French caseâ€"control study. Cancer Causes and Control, 2008, 19, 1147-1160.	0.8	43
136	The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. Supportive Care in Cancer, 2008, 16, 193-200.	1.0	15
137	Promoting evidence-based management of anemia in cancer patients: Background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines. Critical Reviews in Oncology/Hematology, 2008, 65, 32-42.	2.0	4
138	Undernutrition in elderly patients with cancer: Target for diagnosis and intervention. Critical Reviews in Oncology/Hematology, 2008, 67, 243-254.	2.0	92
139	Vulnerable and frail elderly: An approach to the management of the main tumour types. European Journal of Cancer, 2008, 44, 488-493.	1.3	17
140	Erythropoietins should be used according to guidelines. Lancet Oncology, The, 2008, 9, 412-413.	5.1	27
141	Phase III Trial of Consolidation Therapy With Yttrium-90â€"Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. Journal of Clinical Oncology, 2008, 26, 5156-5164.	0.8	431
142	Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients. Blood, 2008, 112, 1309-1309.	0.6	0
143	Occupation and Lymphoid Malignancies: Results From a French Case-Control Study. Journal of Occupational and Environmental Medicine, 2007, 49, 1339-1350.	0.9	19
144	A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkinâ€™s lymphoma. European Journal of Cancer, 2007, 43, 53-54.	1.3	4

#	Article	IF	Citations
145	EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. European Journal of Cancer, 2007, 43, 258-270.	1.3	371
146	Lymphomes et autres tumeurs hÃ©matologiques. , 2007, , 179-206.		1
147	History of infections and vaccinations and risk of lymphoid neoplasms: does influenza immunization reduce the risk?. Leukemia, 2007, 21, 2075-2079.	3.3	15
148	Prise en charge des lymphomes chez les personnes Ã¢gÃ©es. Oncologie, 2007, 9, 214-218.	0.2	0
149	Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care. Supportive Care in Cancer, 2007, 15, 1325-1329.	1.0	5
150	Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leukemia and Lymphoma, 2006, 47, 603-611.	0.6	30
151	Optimising the response to epoetin beta for the treatment of cancer-related anaemia. Current Medical Research and Opinion, 2006, 22, S35-S44.	0.9	1
152	Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. Biostatistics, 2006, 8, 708-721.	0.9	151
153	Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.. Blood, 2006, 108, 486-486.	0.6	41
154	Fludarabine phosphateâ€"CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: A dose-finding study. European Journal of Cancer, 2005, 41, 2630-2636.	1.3	5
155	Variability of quantitative polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicenter study. Haematologica, 2005, 90, 1706-7.	1.7	7
156	EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. European Journal of Cancer, 2004, 40, 2201-2216.	1.3	257
157	Follicular Lymphoma International Prognostic Index. Blood, 2004, 104, 1258-1265.	0.6	1,552
158	Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.. Blood, 2004, 104, 585-585.	0.6	12
159	Reversion of Chemoresistance in Aggressive Lymphoma by Quinine. A Phase II Trial.. Blood, 2004, 104, 4572-4572.	0.6	0
160	EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. European Journal of Cancer, 2003, 39, 2264-2272.	1.3	165
161	Identification of a Novel Proline-Arginine Motif Involved in CIN85-dependent Clustering of Cbl and Down-regulation of Epidermal Growth Factor Receptors. Journal of Biological Chemistry, 2003, 278, 39735-39746.	1.6	115
162	High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Nonâ€"AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. Journal of Clinical Oncology, 2003, 21, 4483-4488.	0.8	308

#	Article	IF	Citations
163	Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Journal of Clinical Oncology, 2003, 21, 2726-2731.	0.8	249
164	Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients. Critical Reviews in Oncology/Hematology, 2002, 43, 219-226.	2.0	7
165	A 1-Kb Bcl-2-PCR Fragment Detection in a Patient With Follicular Lymphoma and Development of a New Diagnostic PCR Method. Diagnostic Molecular Pathology, 2001, 10, 89-94.	2.1	3
166	Expression of the stress-induced p8 mRNA is transiently activated after culture medium change. European Journal of Cell Biology, 2001, 80, 720-725.	1.6	51
167	Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood, 2001, 97, 101-106.	0.6	506
168	Semen analysis and cryoconservation before treatment in Hodgkin's disease. Annals of Oncology, 2000, 11, 679-684.	0.6	42
169	Follicular lymphomas â€" a review of treatment modalities. Critical Reviews in Oncology/Hematology, 2000, 35, 13-32.	2.0	15
170	Current treatment of Hodgkinâ€™s disease. Critical Reviews in Oncology/Hematology, 2000, 35, 49-73.	2.0	9
171	Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas. British Journal of Cancer, 1999, 81, 860-869.	2.9	10
172	Competitive polymerase chain reaction to quantify tumor cells in peripheral blood of patients with T(14;18)-bearing follicular non-Hodgkin's lymphoma: An exploratory study in 8 patients. International Journal of Cancer, 1999, 84, 558-561.	2.3	7
173	Anaplastic large cell lymphoma: clinical features and prognosis in a retrospective series of 72 patients treated in a single institution. European Journal of Cancer, 1999, 35, S331.	1.3	0
174	Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin's lymphoma: Results of a pilot study. International Journal of Radiation Oncology Biology Physics, 1998, 40, 387-390.	0.4	60
175	Polymerase Chain Reaction Diagnosis of t(14;18) From Paraffin-Embedded Tissues Fixed With Holland Bouin Fluid. Diagnostic Molecular Pathology, 1998, 7, 184.	2.1	8
176	Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.. Journal of Clinical Oncology, 1998, 16, 2930-2936.	0.8	46
177	Ã‰tude des anomalies chromosomiques aprÃ¨s radiothÃ©rapie chez des patients traitÃ©s pour lymphome malin non-Hodgkinien. Journal De Chimie Physique Et De Physico-Chimie Biologique, 1998, 95, 832-835.	0.2	0
178	Method for the Purification of Tissue DNA Suitable for PCR After Fixation with BouinÊ¼s Fluid. Diagnostic Molecular Pathology, 1997, 6, 167-173.	2.1	17
179	Is there any place for a wait-and-see policy in stage I0 follicular lymphoma?. Annals of Oncology, 1996, 7, 713-718.	0.6	43
180	Ethmoidal cancers: A retrospective study of 22 cases. International Journal of Radiation Oncology Biology Physics, 1993, 25, 113-116.	0.4	21

#	Article	IF	Citations
181	Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients. European Journal of Cancer & Clinical Oncology, 1991, 27, 1606-1613.	0.9	53
182	A survey in general practice about undergraduate cancer education: Results from gironde (france). Journal of Cancer Education, 1991, 6, 153-157.	0.6	11
183	Adjuvant bacillus Calmette-GuÃ©rin therapy in non-Hodgkin's malignant lymphomas: long-term results of a randomized trial in a single institution.. Journal of Clinical Oncology, 1990, 8, 608-614.	0.8	11
184	Localized follicular lymphomas: Prognosis and survival of stages I and II in a retrospective series of 103 patients. Radiotherapy and Oncology, 1988, 13, 91-98.	0.3	33